Performance-Linked Reimbursement and the Uncertainty of Novel Drugs

Circ Cardiovasc Qual Outcomes. 2022 Jan;15(1):e008642. doi: 10.1161/CIRCOUTCOMES.121.008642. Epub 2022 Jan 18.

Authors

Leah Z Rand¹, Aaron S Kesselheim¹

Affiliation

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, and the Harvard Medical School Center for Bioethics, Boston, MA.

PMID: 35041479
DOI: 10.1161/CIRCOUTCOMES.121.008642

No abstract available

Keywords: Alzheimer disease; drug approval; heart failure; insurance; prescriptions; reimbursement mechanisms.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Drug Costs
Drug Prescriptions
Humans
Insurance, Health, Reimbursement*
Pharmaceutical Preparations*
Reimbursement Mechanisms
Uncertainty

Substances

Pharmaceutical Preparations